Loading... Please wait... Loading... Please wait...
ESTIMATED
05/14/2024
05/14/2024
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.84 | -$0.84 | -$0.84 |
| Q2 2024 | 6 | -$0.82 | -$0.48 | -$0.59 |
| Q3 2024 | 2 | -$0.57 | -$0.57 | -$0.57 |
| Q4 2024 | 2 | -$0.59 | -$0.59 | -$0.59 |
| Q1 2025 | 3 | -$0.64 | -$0.64 | -$0.64 |
| Q2 2025 | 3 | -$0.69 | -$0.69 | -$0.69 |
| Q3 2025 | 3 | -$0.72 | -$0.72 | -$0.72 |
| Q4 2025 | 3 | -$0.71 | -$0.71 | -$0.71 |
Acrivon Therapeutics, Inc. Common Stock last posted its earnings results on Tuesday, May 14th, 2024. The company reported $-0.73 earnings per share for the quarter, topping analysts' consensus estimates of $-0.89 by $0.16. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Acrivon Therapeutics, Inc. Common Stock has generated $-3 earnings per share over the last year ($-2.74 diluted earnings per share) and currently has a price-to-earnings ratio of -2.16. Acrivon Therapeutics, Inc. Common Stock has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, August 9th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/14/2024 | Q1 2024 | -$0.89 | -$0.73 | 0.16 | $0 | $0 | 03/28/2024 | Q4 2023 | -$0.72 | -$0.86 | -0.14 | $0 | $1.88 M | 11/09/2023 | Q3 2023 | -$0.72 | -$0.66 | 0.06 | $0 | 08/11/2023 | Q2 2023 | -$0.68 | -$0.63 | 0.05 | $0 | 05/09/2023 | Q1 2023 | -$0.64 | -$0.51 | 0.13 | $0 | 03/28/2023 | Q4 2022 | -$0.38 | $0 | 09/30/2022 | Q3 2022 | -$0.47 | $0 | 06/30/2022 | Q2 2022 | -$0.44 | $0 | 03/31/2022 | Q1 2022 | -$0.56 | $0 | 12/31/2021 | Q4 2021 | -$0.34 | $0 | 09/30/2021 | Q3 2021 | -$0.17 | $0 |
|---|
A. Acrivon Therapeutics, Inc. Common Stock has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, August 9th, 2024 based off last year's report dates.
A. In the previous quarter, Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) reported $-0.73 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.89 by $0.16.
A. The conference call for Acrivon Therapeutics, Inc. Common Stock's latest earnings report can be listened to online.
A. The conference call transcript for Acrivon Therapeutics, Inc. Common Stock's latest earnings report can be read online.
A. Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) has a recorded net income of $0. Acrivon Therapeutics, Inc. Common Stock has generated $-2.74 earnings per share over the last four quarters.
A. Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) has a price-to-earnings ratio of -2.16 and price/earnings-to-growth ratio is 0.02.
